结肠癌患者术后化疗联合自体级联诱发免疫细胞治疗近期疗效和生活质量观察  

Observe recent curative effect and life quality of colon cancer patients after radical resection treated by chemotherapy in combination with autologous cascade primed immune cells

作　　者：李贵新[1] 刘锦[1] 李肖燕[1] 王文浩[1] 

机构地区：[1]潍坊医学院附属医院肿瘤科,山东潍坊261031

出　　处：《中华肿瘤防治杂志》2014年第19期1548-1552,共5页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的探讨结肠癌术后化疗联合自体级联诱发的免疫（cascade primed immune,CAPRI）细胞治疗近期疗效、毒副作用和生活质量。方法收集2011-01-01-2011-12-31潍坊医学院附属医院肿瘤科50例Ⅱ～Ⅲ期结肠癌患者临床资料,随机分为联合治疗组和单纯化疗组,每组25例。单纯化疗组采用FOLFOX6辅助化疗方案治疗,联合治疗组是在单纯化疗组的基础上加自体CAPRI细胞治疗。观察和比较2组患者的2年复发率、2年生存率、肿瘤标志、毒副作用、睡眠质量和生活质量。结果联合治疗组2年复发率为48.0%（12/25）,显著低于单纯化疗组的76.0%（19/25）,差异有统计学意义,χ^2=4.160,P=0.041。联合治疗组2年生存率为100.0%（25/25）,显著高于单纯化疗组的84.0%（21/25）,差异有统计学意义,χ^2=4.348,P=0.037。治疗结束后联合治疗组CEA均值为（6.50±1.63）ng/mL,单纯化疗组为（19.08±3.402）ng/mL,2组比较差异有统计学意义,t=16.709,P〈0.005;联合治疗组CA19-9均值为（113.27±20.96）U/mL,单纯化疗组为（186.99±16.47）U/mL,2组比较差异有统计学意义,t=13.828,P〈0.005。2组患者治疗后相关不良反应主要为周围神经毒性、骨髓抑制和消化道反应。联合治疗组患者的平均睡眠时间为6.41±0.92,显著长于单纯化疗组的5.20±1.22,P〈0.05;失眠程度低于单纯化疗组,χ^2=6.415,P〈0.05;联合治疗组生活质量显著高于单纯化疗组,χ^2=11.106,P〈0.05。结论结肠癌术后化疗联合自体CAPRI细胞治疗的复发率低,生存率高,近期疗效好,化疗胃肠道反应少,睡眠时间长,失眠少,生活质量高,值得临床推广。OBJECTIVE To study the recent curative effect,adverse reaction and life quality of colon cancer patients after radical resection treated by chemotherapy in combination with autologous cascade primed immune（CAPRI）cells.METHODS 50 stageⅡ-Ⅲ colon cancer patients were randomly divided into two groups,combination treatment group and chemotherapy group,in each group there were 25 cases.25 cases in chemotherapy group were treated with improved FOLFOX6 regimen.25 cases in combination treatment group were treated with improved FOLFOX6 regimen in combination of autologous cascade primed immune（CAPRI）cells.The 2-years recurrence rate,2-years survival rate,tumor markers,adverse reaction,sleep quality and life quality of two groups were observed and studied.RESULTS The2-years recurrence rate of the combination treatment group was significantly lower than that in the chemotherapy group（48.0%vs 76.0%,χ^2=4.160,P〈0.05）.The 2-year survival rate of the combination treatment group was higher than that in the chemotherapy group（100.0%vs 84.0%,χ^2=4.348,P〈0.05）.After treatment,the CEA and CA19-9volume of the combination treatment group were respectively（6.50±1.63）ng/mL and（113.27±20.96）U/mL,which were much more lower than those of the chemotherapy group,（19.08±3.402）ng/mL and（186.99±16.47）U/mL respectively（t=16.709/13.828,P〈0.05）.The incidence of peripheral nerve toxicity and gastrointestinal reaction of the combination treatment group was lower than that of the chemotherapy group（16.0%vs 52.0%,20.0%vs 64.0%,χ^2=7.219/9.934,P〈0.05）.Two groups had no significant difference on bone marrow suppression（36.0% vs 48.0%,χ^2=0.739,P〉0.05）.One case had a low fever in the combination treatment group after CAPRI cells transfusion.The patients in the combination treatment group had significantly longer sleep time than those of the chemotherapy group（P〈0.05）.The insomnia occurrence of the combination treatment group was lower than that of the chemotherapy group（χ^2=6.415,P

关 键 词：结肠癌 自体免疫细胞 化疗 疗效 生活质量 

分 类 号：R735.35[医药卫生—肿瘤]